• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Large owner Bank Of America Corp /De/

    5/6/25 4:27:50 PM ET
    $STSS
    Medical/Dental Instruments
    Health Care
    Get the next $STSS alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
    X
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    BANK OF AMERICA CORP /DE/

    (Last) (First) (Middle)
    BANK OF AMERICA CORPORATE CENTER
    100 N TRYON ST

    (Street)
    CHARLOTTE NC 28255

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Sharps Technology Inc. [ STSS ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    05/01/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    Form filed by One Reporting Person
    X Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    1. Name and Address of Reporting Person*
    BANK OF AMERICA CORP /DE/

    (Last) (First) (Middle)
    BANK OF AMERICA CORPORATE CENTER
    100 N TRYON ST

    (Street)
    CHARLOTTE NC 28255

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    BOFA SECURITIES, INC.

    (Last) (First) (Middle)
    150 N COLLEGE ST
    NC1-028-28-04

    (Street)
    CHARLOTTE NC 28255

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    Explanation of Responses:
    Remarks:
    This statement is jointly filed by Bank of America Corporation ("Bank of America") and BOFA SECURITIES, INC. ("BOFAS"). Bank of America and BOFAS are submitting this form to indicate they are no longer subject to Section 16 as their beneficial ownership has decreased below 10 percent.
    Andres Ortiz, Authorized Signatory of BANK OF AMERICA CORPORATION 05/06/2025
    Andres Ortiz, Authorized Signatory of BOFA SECURITIES, INC 05/06/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $STSS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $STSS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $STSS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Hayes Robert Michael bought $10,750 worth of shares (300,000 units at $0.04), increasing direct ownership by 297% to 400,882 units (SEC Form 4)

      4 - Sharps Technology Inc. (0001737995) (Issuer)

      4/1/25 5:24:02 PM ET
      $STSS
      Medical/Dental Instruments
      Health Care
    • Amendment: Chief Executive Officer Hayes Robert Michael bought $10,072 worth of shares (5,000 units at $2.01), increasing direct ownership by 115% to 9,358 units (SEC Form 4)

      4/A - Sharps Technology Inc. (0001737995) (Issuer)

      12/6/24 5:15:10 PM ET
      $STSS
      Medical/Dental Instruments
      Health Care
    • Chief Executive Officer Hayes Robert Michael bought $10,072 worth of shares (5,000 units at $2.01), increasing direct ownership by 5% to 100,882 units (SEC Form 4)

      4 - Sharps Technology Inc. (0001737995) (Issuer)

      12/5/24 6:12:59 PM ET
      $STSS
      Medical/Dental Instruments
      Health Care

    $STSS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Sharps Technology Inc.

      SC 13G/A - Sharps Technology Inc. (0001737995) (Subject)

      11/13/24 4:50:17 PM ET
      $STSS
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Sharps Technology Inc.

      SC 13G/A - Sharps Technology Inc. (0001737995) (Subject)

      10/9/24 9:01:14 AM ET
      $STSS
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Sharps Technology Inc.

      SC 13G - Sharps Technology Inc. (0001737995) (Subject)

      2/14/24 11:14:11 AM ET
      $STSS
      Medical/Dental Instruments
      Health Care

    $STSS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Sharps Technology Receives ~$100K Initial Purchase Order from Hungarian Vaccine Provider for SecureGard™ Syringes

      Sharps also received an initial qualification purchase order for DisGard™ single-use Sharps Recovery System Company transitions to revenue producing with second purchase order, bringing total recent orders to approximately $500,000 for the quarter NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (NASDAQ: "STSS" and "STSSW") ("Sharps"), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class smart-safety syringe products to the healthcare industry, announces the receipt of a $100,000 purchase order from a Hungarian vaccine provider. This order supports the recently announced $400,000 SoloGard™ order, which is part o

      5/6/25 7:00:00 AM ET
      $STSS
      Medical/Dental Instruments
      Health Care
    • Sharps Technology Secures $400K Initial Purchase Order from U.S. Leader in IV Flushing Solutions as Part of $50 Million SoloGard Supply Agreement

      Milestone order marks first commercial revenue for Sharps Technology under multi-year, 500-million syringe agreementInvestments in best-in-class manufacturing equipment position Sharps to offer differentiated high-volume syringe production to meet long-term contract demand NEW YORK, April 30, 2025 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (NASDAQ: "STSS" and "STSSW") ("Sharps"), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class smart-safety syringe products to the healthcare industry, today announced the receipt of a $400,000 purchase order from a U.S. leader in IV flushing solutions. This marks the first order under the previously announ

      4/30/25 7:00:00 AM ET
      $STSS
      Medical/Dental Instruments
      Health Care
    • Sharps Technology Announces Reverse Stock Split

      NEW YORK, April 24, 2025 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (NASDAQ: "STSS" and "STSSW") ("Sharps"), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class smart-safety syringe products to the healthcare industry, today announced that it will effect a 1-for-300 reverse stock split (the "reverse split") of its common stock, par value $0.0001 per share (the "Common Stock"), that will become effective on April 27, 2025 at 11:59 PM Eastern Time, before the opening of trading on The Nasdaq Capital Market ("Nasdaq"). Sharps has requested that its Common Stock begin trading on April 28, 2025, on a post-reverse split basis on the Nasdaq under th

      4/24/25 11:00:00 AM ET
      $STSS
      Medical/Dental Instruments
      Health Care

    $STSS
    Leadership Updates

    Live Leadership Updates

    See more
    • Sharps Technology Planning To Collaborate With Roncadelle To Support Global Distribution And Sales Of High Quality, Innovative, Safer Drug Delivery Systems

      NEW YORK, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc., (NASDAQ:STSS) (NASDAQ:STSSW), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, is working to create new sales and distribution opportunities through the addition of new North American 3PL partnerships to expand its reach into the global healthcare market. These additional third-party logistics partnerships, along with a developing alliance with Roncadelle Operations, a driving force in the development of safe, novel medical drug delivery devices, would combine the strengths and capabilities of the two companies to develop, market and distribute unique dru

      2/16/24 2:42:54 PM ET
      $STSS
      Medical/Dental Instruments
      Health Care
    • Sharps Technology Appoints Industry Sales and Manufacturing Leader Ben Scheu as Senior Director of Sales

      Key appointment with demonstrated experience in leading sales and marketing operations to oversee commercial initiatives as the Company launches its specialty smart safety syringe products to the market Product qualification and sales initiatives underway as company prepares for U.S. commercial operations NEW YORK, July 12, 2023 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (the "Company") (NASDAQ: "STSS" and "STSSW"), an innovative medical device and drug delivery Company offering patented, best-in-class syringe products, is pleased to announce the appointment of Ben Scheu as Senior Director of Sales to lead commercial operations as the Company prepares to launch products to the market.

      7/12/23 8:33:00 AM ET
      $STSS
      Medical/Dental Instruments
      Health Care
    • Sharps Technology Appoints Justin Page as Vice President of Technical Operations

      NEW YORK, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (the "Company", "Sharps") (NASDAQ: "STSS" and "STSSW"), an innovative medical device and drug delivery Company offering patented, best-in-class syringe products, appoints Justin Page as Vice President of Technical Operations. In his role, Mr. Page will be responsible for managing all aspects of Sharps' engineering operations. His primary focus will be to provide the leadership and technical expertise to support the prefillable syringe collaboration with Nephron Pharmaceuticals at the InjectEZ facility. These efforts will include the support for the injection molding of the specialty components and the high speed assembl

      2/9/23 9:21:23 AM ET
      $STSS
      Medical/Dental Instruments
      Health Care

    $STSS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Large owner Bank Of America Corp /De/

      4 - Sharps Technology Inc. (0001737995) (Issuer)

      5/6/25 4:27:50 PM ET
      $STSS
      Medical/Dental Instruments
      Health Care
    • Chief Executive Officer Hayes Robert Michael bought $10,750 worth of shares (300,000 units at $0.04), increasing direct ownership by 297% to 400,882 units (SEC Form 4)

      4 - Sharps Technology Inc. (0001737995) (Issuer)

      4/1/25 5:24:02 PM ET
      $STSS
      Medical/Dental Instruments
      Health Care
    • Amendment: Chief Executive Officer Hayes Robert Michael bought $10,072 worth of shares (5,000 units at $2.01), increasing direct ownership by 115% to 9,358 units (SEC Form 4)

      4/A - Sharps Technology Inc. (0001737995) (Issuer)

      12/6/24 5:15:10 PM ET
      $STSS
      Medical/Dental Instruments
      Health Care

    $STSS
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by Sharps Technology Inc.

      SCHEDULE 13G - Sharps Technology Inc. (0001737995) (Subject)

      5/7/25 3:55:46 PM ET
      $STSS
      Medical/Dental Instruments
      Health Care
    • Sharps Technology Inc. filed SEC Form 8-K: Other Events

      8-K - Sharps Technology Inc. (0001737995) (Filer)

      5/7/25 9:00:22 AM ET
      $STSS
      Medical/Dental Instruments
      Health Care
    • Sharps Technology Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - Sharps Technology Inc. (0001737995) (Filer)

      5/6/25 8:00:37 AM ET
      $STSS
      Medical/Dental Instruments
      Health Care

    $STSS
    Financials

    Live finance-specific insights

    See more
    • Soligenix and Sharps Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / June 7, 2024 / RedChip Companies will air interviews with Soligenix, Inc. (NASDAQ:SNGX) and Sharps Technology Inc. (NASDAQ:STSS) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, June 8, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Soligenix: https://www.redchip.com/assets/access/sngx_accessSharps Technology: https://www.redchip.com/assets/access/stss_accessIn an exclusive interview, Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix, appears on the RedChip Small Stocks Big Money™ show on B

      6/7/24 9:00:00 AM ET
      $SNGX
      $STSS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
    • Sharps Technology, Reviva Pharmaceuticals, and American Resources Corp. Interviews to Air on the RedChip Money Report(R) on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / September 29, 2023 / RedChip Companies will air interviews with Sharps Technology, Inc. (NASDAQ:STSS), Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) and American Resources Corp. (NASDAQ:AREC) on The RedChip Money Report®, a sponsored program on Bloomberg TV, this Saturday, September 30, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Sharps Technology: https://www.redchip.com/assets/access/stss_accessReviva Pharmaceuticals: https://www.redchip.com/assets/access/rvph_accessAmerican Resources Corp: https://www.redchip.com/assets/access/arec_accessAbout The RedChip

      9/29/23 9:00:00 AM ET
      $AREC
      $RVPH
      $STSS
      Coal Mining
      Energy
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RedChip Launches 'Small Stocks, Big Money' Podcast

      New podcast series shines a spotlight on undervalued small-cap and microcap stocksORLANDO, FL / ACCESSWIRE / August 2, 2023 / RedChip Companies, a renowned international investor relations firm specializing in microcap and small-cap companies,announce the launch of its much-anticipated podcast series, "Small Stocks, Big Money."Hosted by RedChip CEO Dave Gentry and Associate Director Barrett Boone, the "Small Stocks, Big Money" podcast aims to offer a first-hand look at undiscovered small-cap and microcap stocks before they catch the attention of bigger Wall Street players. The series features in-depth interviews with executives from some of the top names in smaller cap stocks, providing list

      8/2/23 12:45:00 PM ET
      $BFRG
      $LTRN
      $RVPH
      $STSS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
      Pharmaceuticals and Biotechnology